Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CervoMed Inc.CRVO · Entity 7338 | EVP, Clinical Development | February 11, 2026 | February 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CervoMed Inc.
Report date February 11, 2026 · Filed February 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.80 · Expires 2036-02-11 | Direct | 30,000 |
Reported balance
After 2026-02-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-11 · Grant · Acquired 30,000 · Balance 30,000 F1: The shares of common stock underlying the award will vest in 36 equal (or as near equal as possible) monthly installments on the last calendar day of each month over a 36-month period commencing February 28, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock underlying the award will vest in 36 equal (or as near equal as possible) monthly installments on the last calendar day of each month over a 36-month period commencing February 28, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 11, 2026 Filed Feb 13, 2026 22:00 UTC | CervoMed Inc. CRVO · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001437749-26-004164 · rdgdoc.xml · derivative · entry 1 Blackburn Kelly · CIK 0001640575 · EVP, Clinical Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2036-02-11 F1 · derivative.exercise_date: The shares of common stock underlying the award will vest in 36 equal (or as near equal as possible) monthly installments on the last calendar day of each month over a 36-month period commencing February 28, 2026. Read SEC document |
| February 04, 2025 Filed Feb 14, 2025 23:00 UTC | CervoMed Inc. CRVO · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 27,000 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0001437749-25-004072 · rdgdoc.xml · derivative · entry 1 Blackburn Kelly · CIK 0001640575 · SVP, Clinical Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2035-02-04 F1 · derivative.exercise_date: The shares of common stock underlying the award will vest in 36 equal (or as near equal as possible) monthly installments on the last calendar day of each month over a 36-month period commencing February 28, 2025. Read SEC document |
| January 26, 2024 Filed Jan 26, 2024 23:46 UTC | CervoMed Inc. CRVO · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001437749-24-002348 · rdgdoc.xml · derivative · entry 1 Blackburn Kelly · CIK 0001640575 · SVP, Clinical Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2034-01-26 F1 · derivative.exercise_date: The shares of common stock underlying the award will vest in 36 equal (or as near equal as possible) monthly installments on the last calendar day of each month over a 36-month period commencing January 31, 2024. Read SEC document |
| September 15, 2023 Filed Sep 15, 2023 22:49 UTC | CervoMed Inc. CRVO · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $5.33 | $0.00 |
DisclosureSEC source: 0001437749-23-026068 · rdgdoc.xml · derivative · entry 1 Blackburn Kelly · CIK 0001640575 · VP, Clinical Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2033-09-15 F1 · derivative.exercise_date: The shares of common stock underlying the award will vest in 36 equal (or as near equal as possible) monthly installments on the last calendar day of each month over a 36-month period commencing September 30, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.